Cancer Incidence in the U.S. Military Population: Comparison with Rates from the SEER Program

Kangmin Zhu,^{1,4} Susan S. Devesa,³ Hongyu Wu,¹ Shelia Hoar Zahm,³ Ismail Jatoi,^{1,4,5} William F. Anderson,³ George E. Peoples,^{1,6} Larry G. Maxwell,^{1,2} Elder Granger,⁷ John F. Potter,^{1,4} and Katherine A. McGlynn³

¹U.S. Military Cancer Institute; ²Walter Reed Army Medical Center, Washington, District of Columbia; ³Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH; ⁴Uniformed Services University of the Health Sciences; ⁵National Naval Medical Center, Bethesda, Maryland; ⁶Brooke Army Medical Center, Fort Sam Houston, Texas; and ⁷Tricare Management Activity, Falls Church, Virginia

Abstract

The U.S. active-duty military population may differ from the U.S. general population in its exposure to cancer risk factors and access to medical care. Yet, it is not known if cancer incidence rates differ between these two populations. We therefore compared the incidence of four cancers common in U.S. adults (lung, colorectal, prostate, and breast cancers) and two cancers more common in U.S. young adults (testicular and cervical cancers) in the military and general populations. Data from the Automated Central Tumor Registry (ACTUR) of the Department of Defense and the nine cancer registries of the Surveillance, Epidemiology and End Results (SEER) of the National Cancer Institute for the years 1990 to 2004 for persons with ages 20 to 59 years were analyzed. Incidence rates were significantly lower

Introduction

The U.S. military population may differ from the U.S. general population in exposure to factors associated with cancer risk, such as physical fitness, smoking, alcohol consumption, diet, and sunlight exposure. Exposures associated with military deployments, such as immunizations and depleted uranium, may also influence cancer risk among military personnel. Yet, compared with the general population, the military population may be generally healthier and more likely to undergo cancer screening and surveillance because military members have free access to health care. Despite these potential differences, cancer incidence rates in the U.S. military and general populations have not been extensively compared.

The elucidation of differences in cancer incidence patterns between the military and general U.S. populations may lead to a better understanding of etiology and the

Grant support: U.S. Military Cancer Institute via the Uniformed Services University of the Health Sciences under the auspices of the Henry M. Jackson Foundation for the Advancement of Military Medicine and the Intramural Research Program of the National Institutes of Health (National Cancer Institute).

Requests for reprints: Kangmin Zhu, U.S. Military Cancer Institute, Walter Reed Army Medical Center, Suite A-109, Building 1, 6900 Georgia Avenue Northwest, Washington, DC 20307-5001. Phone: 202-782-0544; Fax: 202-782-5833. E-mail: kangmin. zhu@amedd.army.mil

Copyright © 2009 American Association for Cancer Research. doi:10.1158/1055-9965.EPI-09-0041 in the military population for colorectal cancer in White men, lung cancer in White and Black men and White women, and cervical cancer in Black women. In contrast, incidence rates of breast and prostate cancers were significantly higher in the military among Whites and Blacks. Incidence rates of testicular cancer did not differ between ACTUR and SEER. Although the numbers of diagnoses among military personnel were relatively small for temporal trend analysis, we found a more prominent increase in prostate cancer in ACTUR than in SEER. Overall, these results suggest that cancer patterns may differ between military and nonmilitary populations. Further studies are needed to confirm these findings and explore contributing factors. (Cancer Epidemiol Biomarkers Prev 2009;18(6):1740–5)

development of preventive strategies for both populations. Researchers have often used data from cancer registries such as the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute to study demographic patterns and trends in incidence and generate study hypotheses (1-7).

Studies on cancer incidence rates in the U.S. military population are few. Using the data from the Department of Defense Automated Central Tumor Registry (ACTUR) and the Defense Manpower Data Center, Thompson et al. (8) found that the incidence of testicular cancer among active-duty members of the military had increased over time. Yamane's (9) study on ACTUR data from 1989 to 2002 for U.S. Air Force active-duty personnel found that cervical, prostate, and vulvar cancers were more frequent than expected, whereas bladder, brain, colorectal, oral squamous cell, and testicular cancers, as well as lymphomas, were less frequent than expected in comparison with national data. These two studies focused on either a specific cancer (8) or a specific military service (9). Therefore, the current study was conducted to gain a broader picture of cancer among military members by comparing incidence patterns of six cancers among all active-duty military personnel and the general U.S. populations.

Materials and Methods

This study was based on nonidentifiable data and was approved by the institutional review boards of U.S. Military

Received 1/13/09; revised 3/9/09; accepted 3/19/09; published online 6/8/09.

The opinions and assertions contained in this article represent the private views of the authors and do not reflect the official views of the U.S. Departments of the Army, Navy, or Defense; National Cancer Institute; or U.S. government.

	Form Approved OMB No. 0704-0188						
maintaining the data needed, and c including suggestions for reducing	llection of information is estimated to completing and reviewing the collect g this burden, to Washington Headqu uld be aware that notwithstanding ar OMB control number.	ion of information. Send comments arters Services, Directorate for Info	regarding this burden estimate rmation Operations and Reports	or any other aspect of the aspect of the second sec	is collection of information, Highway, Suite 1204, Arlington		
1. REPORT DATE JAN 2008		3. DATES COVERED -					
4. TITLE AND SUBTITLE	5a. CONTRACT NUMBER						
Cancer Incidence i from the SEER Pr	5b. GRANT NUMBER						
	5c. PROGRAM ELEMENT NUMBER						
6. AUTHOR(S)	5d. PROJECT NUMBER						
	5e. TASK NUMBER						
		5f. WORK UNIT NUMBER					
7. PERFORMING ORGANI U.S. Military Canc	8. PERFORMING ORGANIZATION REPORT NUMBER						
9. SPONSORING/MONITO	RING AGENCY NAME(S) A	AND ADDRESS(ES)		10. SPONSOR/MONITOR'S ACRONYM(S)			
	11. SPONSOR/MONITOR'S REPORT NUMBER(S)						
12. DISTRIBUTION/AVAIL Approved for publ	LABILITY STATEMENT ic release, distributi	on unlimited					
13. SUPPLEMENTARY NO	DTES						
14. ABSTRACT							
15. SUBJECT TERMS							
16. SECURITY CLASSIFIC	18. NUMBER	19a. NAME OF					
a. REPORT unclassified			- ABSTRACT UU	OF PAGES 6	RESPONSIBLE PERSON		

Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std Z39-18 Cancer Institute, Armed Forces Institute of Pathology, and the National Cancer Institute.

ACTUR was established in 1986 as the cancer database and clinical tracking system for the Department of Defense. Military medical treatment facilities are required to report cancer data on all Department of Defense beneficiaries, including active-duty military personnel and their family members, retired military personnel, and Reserve and National Guard personnel who are temporarily activated. For the current study, data on diagnoses from 1990 to 2004 were analyzed.

For this study, data analyses were confined to personnel on active military duty. Records for retired military personnel, reservists, National Guard personnel, and family members are less complete because they may get medical care outside the military system.

To reconcile duplicate records for the same patient so that only one summary record existed for each primary cancer, we used data consolidation procedures based on national and state cancer registry guidelines (10-12). The guidelines were used to determine multiple primary malignancies and to select the best information on diagnostic and demographic variables from the multiple records per person that exist in ACTUR.

The following items from the ACTUR database were used in the data analysis: primary cancer site, age at diagnosis, gender, and race. Diagnoses are classified using the International Classification of Diseases for Oncology (13). The annual numbers of active-duty military personnel were used to calculate incidence rates. The numbers were obtained from the Defense Manpower Data Center, which maintains demographic and military data on personnel in all military services.

National comparison data were obtained from the SEER program of the National Cancer Institute (14). SEER collects and publishes cancer statistics from populationbased cancer registries. For the current study, cancer rates for 1990 to 2004 were drawn from the SEER-9 Registries Database (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco–Oakland, Seattle–Puget Sound, and Utah), covering ~10% of the U.S. population.

The age distribution of the active military population differs substantially from that of the general population in that there are no members of the military younger than 17 y old and few 60 y or older. Because the small number of persons <20 y and \geq 60 y would generate statistically unstable rates, analyses were restricted to persons with ages 20 to 59 y. Furthermore, within this age range, the active-duty military population is considerably younger than the general U.S. population. To give more weight to the age groups with a large number of active-duty members and thereby generate more stable rates, the 1990 to 2004 military population was used as the standard population for age adjustment. Age-adjusted incidence rates, incidence rate ratios, and their 95% confidence intervals (95% CI) were calculated. The Tiwari method was used to estimate confidence intervals (15). Because the military population was used as the standard population for these calculations, the absolute incidence rates in this study differ from those based on U.S. population data.

We analyzed the incidence of six cancers (lung, colorectum, prostate, testis, breast, and cervix) by gender, year of diagnosis (1990-1994, 1995-1999, 2000-2004), and race (White, Black). Small numbers of military patients precluded the examination of data among other racial or ethnic groups. Small numbers also precluded trend analyses of lung cancer and testicular cancer among Black men, colorectal cancer and lung cancer among women, and cervical cancer among Black women.

Results

Among the six cancers examined, the most common among active-duty military personnel (the ACTUR population) was testicular cancer (n = 1,826), followed by prostate (n = 910), breast (n = 864), and colorectal (n = 738) cancers. In the SEER population, breast cancer (n =107,601) among women was the most common cancer in this 20 to 59 year age group, followed by lung (n =46,083), prostate (n = 42,751), and colorectal (n = 36,092) cancers (Table 1). These frequencies reflect the dramatic differences in the size and gender/age distribution of the two populations. Colorectal cancer incidence among White men was significantly lower in the ACTUR population than the SEER population (incidence rate ratio, 0.83), but there were no differences among the other three race/gender groups. Lung cancer incidence was

Table 1. Cancer incidence in the U.S. active-duty military population and the SEER program for breast, lung, prostate, colorectal, testicular, and cervical cancers; ages 20 to 59 years; 1990-2004; by race and gender

Cancer site	e ACTUR				SEER					ACTUR:SEER						
	Whites			Blacks		Whites		Blacks			Whites		Blacks			
	Count	Rate*	Rate 95% CI	Count	Rate*	Rate 95% CI	Count	Rate*	Rate 95% CI	Count	Rate*	Rate 95% CI	IRR	IRR 95% CI	IRR	IRR 95% CI
Men Colorectur	E10	2 40	2 10 2 20	146	4.90	4.06 5.82	17 (12	4.00	4 00 4 25	2 (02	E 01	4.0E.E.(9	0.02	0.75.0.01	0.02	0.75 1.11
Lung	n 513 277	1.85		$ 146 \\ 70 $		4.06-5.83			4.09-4.33			4.95-5.68 6.83-7.60				
Prostate	689	4.32	4.00-4.65	221		8.64-11.57				7,576						
Testis	1,756	12.63	12.05-13.23	3 70	1.97	1.54-2.50	9,318	13.11	12.79-13.43	243	2.17	1.87-2.52	0.96	0.91-1.02	0.91	0.67-1.21
Women				• •												
Colorectur		0	2.41-4.31	30					3.29-3.53			4.69-5.39				
Lung	_30	1.99	1.34-2.84	25		2.78-7.33						3.99-4.56				
Breast Cervical	543 113		33.43-39.64 6.02-8.80	4 321 30		40.65-51.61 2.30-4.90			30.29-30.96 7.70-8.14			32.54-34.31 7.47-8.49				

Abbreviation: IRR, incidence rate ratio

*Rates are per 100,000 person-years and age-adjusted to active-duty military population with ages 20 to 59 years.

significantly lower in all groups of the ACTUR population compared with the SEER population, except for Black women (incidence rate ratio, 0.58, 0.69, 0.35, 1.10 among White men, White women, Black men, and Black women, respectively). Cervical cancer incidence was significantly lower in the ACTUR compared with SEER among Blacks (incidence rate ratio, 0.43) but not among Whites (incidence rate ratio, 0.92).

In contrast to the lower rates of colorectal, lung and cervical cancers among some military personnel, the incidence rates of prostate and breast cancers were significantly higher in the ACTUR population (prostate cancer incidence rate ratio is 2.12 and 2.09, and breast cancer incidence rate ratio is 1.19 and 1.37 among Whites and Blacks, respectively). Testicular cancer rates did not differ between the ACTUR and SEER populations (incidence rate ratio, 0.96 and 0.91 among Whites and Blacks).

Figure 1 and Table 2 show the temporal trends in raceand gender-specific age-adjusted incidence rates among the ACTUR and SEER populations from 1990-1994 to 2000-2004. Among men, colorectal cancer incidence increased significantly among ACTUR and SEER Whites (33% and 23%, respectively), but not Blacks. In contrast, lung cancer rates decreased 43% and 30% among ACTUR and SEER White men. Prostate cancer rates increased significantly among Whites and Blacks in both populations. The increases in both racial groups seemed more prominent in ACTUR than in SEER: rates doubled among SEER Whites but tripled among ACTUR Whites. Among Blacks, SEER rates rose to more than double, while among ACTUR Blacks, rates increased more than 8-fold. Testicular cancer rates rose nonsignificantly among White men in both populations.

Among women, breast cancer rates did not change significantly in either population except among SEER Blacks (incidence rate ratio, 0.92). Cervical cancer rates among White women declined nonsignificantly in ACTUR (incidence rate ratio, 0.93) and significantly in SEER (incidence rate ratio, 0.80).

Discussion

Our study found differences in cancer incidence rates between military personnel and the general population. Rates were lower among military personnel than the general population for colorectal, lung, and cervical cancers. However, for colorectal cancer, the difference in rates between the two populations was significant only among White males and, for cervical cancer, only among Black females. Rates were significantly higher for prostate and breast cancers, and the rates of prostate cancer over time rose more rapidly among military personnel. There were no significant differences between the populations in the rates of testicular cancer.

It is unclear why White men in the military would have lower colorectal cancer incidence than other White men, although several factors may be related to the difference. Men in the military are a selected population because individuals with certain diseases or conditions are not eligible for military service. For example, military personnel may be less likely to be obese or to have familial polyposis. Individuals who enter the military are more physically active because of the fitness standards required for entry (9). Once in the military, servicemen might maintain healthier lifestyles than men in the general population. For instance, military personnel are generally engaged in more rigorous physical activities than their civilian counterparts because they must pass the military physical fitness tests and meet the military weight standards.^{8,9} In addition, military personnel are granted free access to medical care and cancer screening services. As a result, precancerous lesions such as colonic polyps may be more likely to be detected and treated early (16-18) in the military population, thereby potentially reducing the risk for colorectal cancer. These differences between the military and general populations were not significant for women and Black men, although the same direction in incidence rate ratio was observed. Although this might be related to a relatively small number of patients for these groups, further research is needed to understand whether the racial/ gender differences exist.

The significantly lower risk for cervical cancer among servicewomen versus nonservicewomen might be related to greater access to medical care and cancer screening services in the military. Cervical cancer screening can result in the detection of precancerous lesions and the treatment of these lesions may lower cervical cancer incidence rates. In the general population, Black women are more likely than White women to have a low family income and a lack of usual source of medical care, factors that are associated with a lower rate of cervical cancer screening (19, 20). In the military population, access to medical care is equal between Black and White women. This might have produced the larger differences between the two populations in incidence of cervical cancer in Black women. Further research is needed on why the incidence rate is lower in Black women than White women in the military.

Lung cancer rates were significantly lower in the military among all groups except Black women. Cigarette smoking is the single most important risk factor for lung cancer. In the past, the prevalence of smoking in the military, particularly among junior enlisted military personnel (21, 22), exceeded that in the general population (23, 24). Therefore, the lower rate of lung cancer in military personnel is an unanticipated finding. It is possible however that smoking patterns, which influence the risk for lung cancer, differ among military and nonmilitary personnel. Although most smokers in the general population begin smoking in their teens, adult-onset smoking is a phenomenon seen in military populations (25). It is also possible that, because of the emphasis on physical activity in the military, servicepersons smoke fewer cigarettes than their counterparts not in the military.

The prevalence of smoking in the United States has been declining, especially among males, and lung cancer rates have been decreasing, especially among the younger and middle age groups (26). Among military members, cigarette smoking dropped sharply from 1980 to 1998, whereas it increased somewhat afterward (27). The lower rates in the military compared with SEER are welcome observations.

Prostate cancer rates in the military were twice those in the general population, and breast cancer rates were 20% to 40% higher. These differences may be related to free

⁸ http://www.military.com/military-fitness/fitness-test-prep/physicalfitness-test-standards ⁹ http://www.apft.net/

access to medical care for the military population. Military members may have more frequent visits to the doctor and thus are more likely to undergo breast and prostate cancer screening (28, 29). Several studies have now confirmed that cancer screening is associated with increases in breast and prostate cancer incidence rates (30-32).

In addition to the potential differences in screening practices between the military and general populations,



Figure 1. Trends in cancer incidence rates among active-duty members and in the SEER program 1990-1994 to 2000-2004 (rates age-adjusted using the active-duty military population with ages 20-59 y).

Cancer site		1990-1994		IRR* (95% CI [†])	
	Count	Rate ⁺ (95% CI)	Count	Rate ⁺ (95% CI)	
Colorectum					
White males					
ACTUR	171	3.08 (2.63-3.57)	182	4.09 (3.51-4.74)	1.33 (1.07-1.65)
SEER	5,099	3.84 (3.64-4.05)	6,802	4.74 (4.49-4.99)	1.23 (1.14-1.33)
Black males	,				
ACTUR	58	5.17 (3.82-6.84)	47	5.16 (3.74-6.95)	1.00 (0.65-1.54)
SEER	727	5.62 (4.96-6.34)	1,105	5.40 (4.82-6.03)	0.96 (0.81-1.14)
Lung			,	· · · · ·	()
White males					
ACTUR	130	2.35 (1.96-2.79)	63	1.34 (1.02-1.72)	0.57 (0.41-0.78)
SEER	7.137	3.83 (3.65-4.02)	6,672	2.70 (2.54-2.86)	0.70 (0.65-0.76)
Prostate	,,10,	0.00 (0.00 1.02)	0,07 =	200 (200 1 2000)	
White males					
ACTUR	112	2.07 (1.70-2.49)	352	6.55 (5.87-7.28)	3.17 (2.55-3.96)
SEER	6.877	1.25 (1.18-1.31)	16,704	2.63 (2.53-2.72)	2.11(1.98-2.25)
Black males	0,011	1.20 (1.10 1.01)	10,701	2.00 (2.00 2.72)	2.11 (1.90 2.20)
ACTUR	11	1.85 (0.89-3.31)	137	15.39 (12.81-18.33)	8.33 (4.51-17.80)
SEER	1,258	2.32 (2.07-2.61)	3,824	6.33 (5.95-6.75)	2.73 (2.39-3.11)
Testis	1,200	2.02 (2.07 2.01)	0,021	0.55 (0.55 0.75)	2.75 (2.57 5.11)
White males					
ACTUR	634	11.18 (10.33-12.09)	515	13.09 (11.98-14.28)	1.17 (1.04-1.32)
SEER	2.937	12.57 (12.04-13.12)	3,327	14.05 (13.48-14.64)	1.17 (1.04-1.02) 1.12 (1.05-1.19)
Breast	2,931	12.57 (12.04-15.12)	5,527	14.03 (13.40-14.04)	1.12 (1.05-1.19)
White females					
ACTUR	164	33.23 (28.19-38.91)	190	37.31 (32.07-43.13)	1.12 (0.90-1.40)
SEER	27,067	30.43 (29.87-31.00)	35,275	30.68 (30.10-31.28)	1.12(0.90-1.40) 1.01(0.98-1.04)
Black females	27,007	30.43 (29.87-31.00)	55,275	30.08 (30.10-31.28)	1.01 (0.96-1.04)
ACTUR	76	40.54 (26.13-59.75)	122	45.12 (37.38-54.03)	1.11 (0.74-1.80)
SEER	3,448	34.96 (33.34-36.63)	4,862	32.32 (30.88-33.81)	0.92 (0.87-0.99)
Cervix					
White females	10		20		0.02 (0.5(1.52)
ACTUR	43	7.29 (5.25-9.88)	30	6.80 (4.57-9.70)	0.93 (0.56-1.52)
SEER	3,254	8.67 (8.28-9.07)	2,830	6.94 (6.58-7.30)	0.80 (0.75-0.86)

Table 2. Incidence in the U.S. active-duty military population and the SEER program for breast, lung, prostate, colorectal, testicular, and cervical cancers by race and gender; ages 20 to 59 years; comparison of 2000-2004 to 1990-1994

*Incidence rate ratio of 2000-2004 compared with 1990-1994

*Rates are per 100,000 person-years and age-adjusted to active-duty military population.

variations in some risk factors may have contributed to the higher breast and prostate cancer rates in the military. With respect to breast cancer, military women may differ from those in the general population in reproductive history such as age at first birth, parity, and use of contraceptives. Military women may be more likely to use oral contraceptive pills because of a need or desire for anovulatory cycles and menstrual regulation and the easier access to prescription drugs. As shown in our recent analysis, 34% of active-duty women and 29% of women in the general population used oral contraceptive pills in the preceding 12 months. Oral contraceptive pill use has been shown to increase the risk for breast cancer, particularly in younger women (33, 34). Military women are also more likely to be engaged in industrial jobs than females in the general population and hence potentially more likely to be exposed to chemicals that may be related to breast cancer (35). A study in military women showed that those with ages 34 years or younger had higher age-specific incidence rates of breast cancer than women in the general population, and the incidence was higher among military women with a moderate to high exposure to volatile organic chemicals than those with low or no exposure (35). Our findings of higher breast cancer rates in military women are consistent with those from this study.

In regard to prostate cancer, although the results have been inconsistent, depleted uranium (the material used in armor penetrators) has been suggested to increase the risk for prostate cancer (36). Because military personnel are more likely to be exposed to depleted uranium, these factors may have contributed to the increased risk for prostate cancer in military members, although most of the elevated rates and more dramatic increase over time in rates in military personnel might be attributed to screening in the population.

A number of factors may affect the comparability of the ACTUR and SEER databases. First, the two databases may differ in completeness of reporting. Although cancer reporting is required by the Department of Defense and regular training is provided to cancer registrars, some military treatment facilities do not have American College of Surgeons-approved cancer programs. Some small clinics and hospitals may not have dedicated cancer registrars. In addition, some military personnel may be diagnosed and treated outside military treatment facilities through spouses' health insurance. Nevertheless, as long as military personnel are subsequently seen in a military treatment facility, which is usually true, they are included in the ACTUR data. These suggest that underreporting of cancer in ACTUR is of potential concern. However, the higher (rather than lower) breast and prostate rates in the military suggest that other factors beyond reporting are related to the observed differences between the two populations. Second, data consolidation procedures may vary between our analysis of the ACTUR data set and SEER because no shared standards for case consolidation

have been developed to date.¹⁰ Nevertheless, it is unlikely that data consolidation differences are substantial enough to account for the observed large differences in incidence rates of certain cancers such as prostate cancer. Our findings of similarities and differences in incidence rates between military personnel and the general population according to cancer, race, gender, and over time suggest that further research on risk factors and cancer screening practices in the military are warranted.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Annette Anderson of the Armed Forces Institute of Pathology for her help in obtaining the ACTUR data; William Mahr and Anne Dimke of U.S. Military Cancer Institute for their administrative support and help; Dr. Sally Bushhouse of Minnesota Cancer Surveillance System for providing the Minnesota Patient and Tumor Resolution Algorithms document; John Lahey of IMS, Inc., and David Check of Division of Cancer Epidemiology and Genetics, National Cancer Institute for figure development; Dr. Benedict Diniega, Col. John Kugler, and Capt. David Arday of the Department of Defense Health Affairs for their insightful comments on the initial work on this topic; Dr. Joseph F. Fraumeni, Jr., and Dr. Robert N. Hoover of Division of Cancer Epidemiology and Genetics, National Cancer Institute, and Dr. Kimberley Marshall of Tricare Management Activity for their encouragement and support for this collaborative project.

¹⁰ http://training.seer.cancer.gov/module_registry_operations/ unit03_sec03_part05_case_consolidation.html

References

- 1. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001;23:3–13.
- McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003;97:63–70.
- Wang SS, Sherman ME, Hildesheim A, Lacey JV, Jr., Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004;100:1035–44.
- Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294–9.
- Jatoi I, Anderson WF, Rao SR, Devesa SS. Breast cancer trends among black and white women in the United States. J Clin Oncol 2005;23: 7836–41.
- Irby K, Anderson WF, Henson DE, Devesa SS. Emerging and widening colorectal carcinoma disparities between Blacks and Whites in the United States (1975-2002). Cancer Epidemiol Biomarkers Prev 2006;15: 792–7.
- Shah MN, Devesa SS, Zhu K, McGlynn KA. Trends in testicular germ cell tumours by ethnic group in the United States. Int J Androl 2007;30: 206–13; discussion 13-4.
- Thompson IM, Optenberg S, Byers R, Dove M. Increased incidence of testicular cancer in active duty members of the Department of Defense. Urology 1999;53:806–7.

- Yamane GK. Cancer incidence in the U.S. Air Force: 1989-2002. Aviat Space Environ Med 2006;77:789–94.
- NAACCR. ATL site pairs table. (http://www.naaccr.org/filesystem/ other/ATL_Sitepairs_Table.xls).
- 11. Multiple and histology coding rules. NCI SEER Program, 2007.
- MCSS. MN-PATRL: technical specifications for automated record consolidation. Minnesota Department of Health, 1997-2003.
- Fritz A, Jack A, Shanmugaratnam K, et al. International classification of disease for oncology, 3rd ed. Geneva: World Health Organization; 2000.
- Ries L, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. National Cancer Institute; 2008.
- Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for ageadjusted cancer rates. Stat Methods Med Res 2006;15:547–69.
- Brawer MK. Prostatic intraepithelial neoplasia: an overview. Rev Urol 2005;7 Suppl 3:S11–8.
- Schoenfield L, Jones JS, Zippe CD, et al. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. BJU Int 2007;99:770–4.
- Giovannicci E, Wu K. Cancers of the colon and rectum. In: Schottenfeld D, Fraumeni JFJ, editors. Cancer epidemiology and prevention. Oxford: Oxford University Press; 2006. p. 809–29.
- Hewitt M, Devesa SS, Breen N. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. Prev Med 2004;39:270–8.
- Peterson N, Murff H, Cui Y, Hargreaves M, Fowke J. Papanicolaou testing among women in the Southern United States. J Womens Health 2008;17:939–46.
- Cunradi C, Moore R, Ames G. Contribution of occupational factors to current smoking among active-duty U.S. Navy careerists. Nicotine Tob Res 2008;10:429–37.
- Peterson AL, Severson HH, Andrews JA, et al. Smokeless tobacco use in military personnel. Mil Med 2007;172:1300–5.
- Chisick M, Poindexter F, York A. Comparing tobacco use among incoming recruits and military personnel on active duty in the United States. Tob Control 1998;7:219–21.
- Bray RM, Marsden ME, Peterson MR. Standardized comparisons of the use of alcohol, drugs, and cigarettes among military personnel and civilians. Am J Public Health 1991;81:865–9.
- Haddock CK, Lando HA, Pyle SA, et al. Prediction of adult-onset smoking initiation among U.S. Air Force recruits using the pierce susceptibility questionnaire. Am J Prev Med 2005;28:424–9.
- Jemal A, Cokkinides VE, Shafey O, Thun MJ. Lung cancer trends in young adults: an early indicator of progress in tobacco control (United States). Cancer Causes Control 2003;14:579–85.
- Bray RM, Hourani LL. Substance use trends among active duty military personnel: findings from the United States Department of Defense Health Related Behavior Surveys, 1980-2005. Addiction 2007;102:1092–101.
- Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008;17:636–44.
- Breast cancer screening in the military health system (MHS): a national quality management program special study. ACS Federal Healthcare, Inc.; 2002.
- Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9:445–52.
- Lantz PM, Remington PL, Newcomb PA. Mammography screening and increased incidence of breast cancer in Wisconsin. J Natl Cancer Inst 1991;83:1540–6.
- 32. Jonsson H, Johansson R, Lenner P. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 2005;117:842–7.
- Pymar HC, Creinin MD. The risks of oral contraceptive pills. Semin Reprod Med 2001;19:305–12.
- Yankaskas BC. Epidemiology of breast cancer in young women. Breast Dis 2005;23:3–8.
- Rennix CP, Quinn MM, Amoroso PJ, Eisen EA, Wegman DH. Risk of breast cancer among enlisted Army women occupationally exposed to volatile organic compounds. Am J Ind Med 2005;48:157–67.
- Ritz B. Cancer mortality among workers exposed to chemicals during uranium processing. J Occup Environ Med 1999;41:556–66.